PMCB
PharmaCyte Biotech, Inc.
Key Financials
Operating Income
$-6853713
↓ 56.6%
Gross Profit
$0
NaN%
Net Income
$-19424654
↓ 163.4%
Revenue
$0
NaN%
EPS (Diluted)
$-2.77
↓ 186.8%
Total Assets
$46.8M
↓ 15.3%
Total Liabilities
$11.8M
↑ 259.2%
Shareholders' Equity
$33.3M
↓ 35.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 7/29/2026 | View on SEC |
| 4/A | 7/17/2026 | View on SEC |
| 4/A | 7/17/2026 | View on SEC |
| 4/A | 7/17/2026 | View on SEC |
| 4/A | 7/17/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PMCB |
| Company Name | PharmaCyte Biotech, Inc. |
| CIK | 1157075 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0430 |
| State of Incorporation | NV |
| Phone | (917) 595.2850 |